JA

Profile

Research

Social

Other

Shirakami Yoshifumi

白神　宜史

Institute for Radiation Sciences, Specially Appointed Associate Professor (Full Time)

yoshifumi_shirakami irs.osaka-u.ac.jp

keyword radiochemistry，targeted alpha therapy，radiopharmaceuticals，nuclear medicine，theranostics

Research History

  • 2022/04 - Present, Osaka University, Forefront Research Center, Graduate School of Science, Specially Appointed Associated Professor
  • 2019/04 - Present, Osaka University, Institute for Radiation Sciences, Specially appointed Associate Professor
  • 2021/04 - 2022/03, Osaka University
  • 2020/04 - 2021/03, Osaka University, Research Center for Nuclear Physics
  • 2015/06 - 2019/03, Osaka University Graduate School of Medicine, Nuclear Medicine and Tracer Kinetics, Specially Appointed Associate Professor
  • 1984/04 - 2015/05, Nihon Medi-Physics Co.,Ltd, Research Centre

Research Areas

  • Life sciences, Pharmaceuticals - chemistry and drug development

Professional Memberships

  • JAPAN RADIOLOGICAL SOCIETY
  • JAPANESE SOCIETY OF NUCLEAR MEDICINE

Papers

  • Comparison of Nuclear Medicine Therapeutics Targeting PSMA among Alpha-Emitting Nuclides, Kazuko Kaneda-Nakashima,Yoshifumi Shirakami,Yuichiro Kadonaga,Tadashi Watabe,Kazuhiro Ooe,Xiaojie Yin,Hiromitsu Haba,Kenji Shirasaki,Hidetoshi Kikunaga,Kazuaki Tsukada,Atsushi Toyoshima,Jens Cardinale,Frederik L. Giesel,Koichi Fukase, International Journal of Molecular Sciences, MDPI AG, Vol. 25, No. 2, p. 933-933, 2024/01/11
  • Development and Utility of an Imaging System for Internal Dosimetry of Astatine-211 in Mice, Atsushi Yagishita,Miho Katsuragawa,Shin’ichiro Takeda,Yoshifumi Shirakami,Kazuhiro Ooe,Atsushi Toyoshima,Tadayuki Takahashi,Tadashi Watabe, Bioengineering, MDPI AG, Vol. 11, No. 1, p. 25-25, 2023/12/26
  • Evaluation of Astatine-211-Labeled Fibroblast Activation Protein Inhibitor (FAPI): Comparison of Different Linkers with Polyethylene Glycol and Piperazine, Ayaka Aso,Hinako Nabetani,Yoshifumi Matsuura,Yuichiro Kadonaga,Yoshifumi Shirakami,Tadashi Watabe,Taku Yoshiya,Masayoshi Mochizuki,Kazuhiro Ooe,Atsuko Kawakami,Naoya Jinno,Atsushi Toyoshima,Hiromitsu Haba,Yang Wang,Jens Cardinale,Frederik Lars Giesel,Atsushi Shimoyama,Kazuko Kaneda-Nakashima,Koichi Fukase, International Journal of Molecular Sciences, MDPI AG, Vol. 24, No. 10, p. 8701-8701, 2023/05/12
  • Fibroblast Activation Protein Inhibitor Theranostics: Preclinical Considerations., Kazuko Kaneda-Nakashima,Yoshifumi Shirakami,Yuichiro Kadonaga,Tadashi Watabe, PET clinics, Vol. 18, No. 3, p. 397-408, 2023/03/28
  • Mathematical Model for Evaluation of Tumor Response in Targeted Radionuclide Therapy with 211At Using Implanted Mouse Tumor, Yoshiharu Yonekura,Hiroshi Toki,Tadashi Watabe,Kazuko Kaneda-Nakashima,Yoshifumi Shirakami,Kazuhiro Ooe,Atsushi Toyoshima,Hiroo Nakajima,Noriyuki Tomiyama,Masako Bando, International Journal of Molecular Sciences, Vol. 23, No. 24, 2022/12/15
  • Effect to Therapy of Sodium-Iodine Symporter Expression by Alpha-Ray Therapeutic Agent via Sodium/Iodine Symporter., Kazuko Kaneda-Nakashima,Yoshifumi Shirakami,Tadashi Watabe,Kazuhiro Ooe,Takashi Yoshimura,Atsushi Toyoshima,Yang Wang,Hiromitsu Haba,Koichi Fukase, International journal of molecular sciences, Vol. 23, No. 24, 2022/12/07
  • Targeted α-therapy using astatine (211At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound., Tadashi Watabe,Kazuko Kaneda-Nakashima,Yoshifumi Shirakami,Yuichiro Kadonaga,Kazuhiro Ooe,Yang Wang,Hiromitsu Haba,Atsushi Toyoshima,Jens Cardinale,Frederik L Giesel,Noriyuki Tomiyama,Koichi Fukase, European journal of nuclear medicine and molecular imaging, Vol. 50, No. 3, p. 849-858, 2022/11/08
  • Substrate Study for Dihydroxyboryl Astatine Substitution Reaction with Fibroblast Activation Protein Inhibitor (FAPI), Ayaka Aso,Kazuko Kaneda-Nakashima,Hinako Nabetani,Yuichiro Kadonaga,Yoshifumi Shirakami,Tadashi Watabe,Taku Yoshiya,Masayoshi Mochizuki,Yuki Koshino,Kazuhiro Ooe,Atsuko Kawakami,Naoya Jinno,Atsushi Toyoshima,Hiromitsu Haba,Yang Wang,Jens Cardinale,Frederik L. Giesel,Atsushi Shimoyama,Koichi Fukase, Chemistry Letters, The Chemical Society of Japan, Vol. 51, No. 11, p. 1091-1094, 2022/11/05
  • Dioxetane derivative containing carboxy group as a chemiluminophore-introducing reagent., Yukie Nohara,Shun Masuda,Kazuko Kaneda-Nakashima,Yoshifumi Shirakami,Masakatsu Matsumoto,Taku Yoshiya, Chembiochem : a European journal of chemical biology, Vol. 23, No. 24, 2022/10/26
  • Comparison of the Therapeutic Effects of [211At]NaAt and [131I]NaI in an NIS-Expressing Thyroid Cancer Mouse Model., Tadashi Watabe,Yuwei Liu,Kazuko Kaneda-Nakashima,Tatsuhiko Sato,Yoshifumi Shirakami,Kazuhiro Ooe,Atsushi Toyoshima,Eku Shimosegawa,Yang Wang,Hiromitsu Haba,Takashi Nakano,Atsushi Shinohara,Jun Hatazawa, International journal of molecular sciences, Vol. 23, No. 16, 2022/08/21
  • 211At標識PSMA-5を用いた標的アルファ線治療 非臨床での評価, 渡部 直史,兼田 加珠子,白神 宜史,角永 悠一郎,大江 一弘,王 洋,羽場 宏光,豊嶋 厚史,深瀬 浩一, 核医学, (一社)日本核医学会, Vol. 59, No. Suppl., p. S464-S464, 2022/08
  • Synthesis of [211At]4-astato-L-phenylalanine by dihydroxyboryl-astatine substitution reaction in aqueous solution, Yoshifumi Shirakami,Tadashi Watabe,Honoka Obata,Kazuko Kaneda,Kazuhiro Ooe,Yuwei Liu,Takahiro Teramoto,Atsushi Toyoshima,Atsushi Shinohara,Eku Shimosegawa,Jun Hatazawa,Koichi Fukase, Scientific Reports, Springer Science and Business Media LLC, Vol. 11, No. 1, p. 12982-12982, 2021/12
  • Neopentyl Glycol as a Scaffold to Provide Radiohalogenated Theranostic Pairs of High In Vivo Stability., Hiroyuki Suzuki,Yuta Kaizuka,Maho Tatsuta,Hiroshi Tanaka,Nana Washiya,Yoshifumi Shirakami,Kazuhiro Ooe,Atsushi Toyoshima,Tadashi Watabe,Takahiro Teramoto,Ichiro Sasaki,Shigeki Watanabe,Noriko S Ishioka,Jun Hatazawa,Tomoya Uehara,Yasushi Arano, Journal of medicinal chemistry, Vol. 64, No. 21, p. 15846-15857, 2021/11/11
  • Fibroblast activation protein targeted therapy using [177Lu]FAPI-46 compared with [225Ac]FAPI-46 in a pancreatic cancer model., Yuwei Liu,Tadashi Watabe,Kazuko Kaneda-Nakashima,Yoshifumi Shirakami,Sadahiro Naka,Kazuhiro Ooe,Atsushi Toyoshima,Kojiro Nagata,Uwe Haberkorn,Clemens Kratochwil,Atsushi Shinohara,Jun Hatazawa,Frederik Giesel, European journal of nuclear medicine and molecular imaging, Vol. 49, No. 3, p. 871-880, 2021/09/18
  • Extended single-dose toxicity study of [211At]NaAt in mice for the first-in-human clinical trial of targeted alpha therapy for differentiated thyroid cancer., Tadashi Watabe,Kazuko Kaneda-Nakashima,Kazuhiro Ooe,Yuwei Liu,Kenta Kurimoto,Takashi Murai,Yuka Shidahara,Kenji Okuma,Masanori Takeuchi,Masayuki Nishide,Atsushi Toyoshima,Atsushi Shinohara,Yoshifumi Shirakami, Annals of nuclear medicine, Vol. 35, No. 6, p. 702-718, 2021/06
  • Development of GGAG alpha camera system for targeted alpha radionuclide therapy research, S. Yamamoto,T. Watabe,K. Kaneda-Nakashima,Y. Shirakami,K. Ooe,A. Toyoshima,T. Teramoto,A. Shinohara,J. Hatazawa, Journal of Instrumentation, IOP Publishing, Vol. 16, No. 06, p. P06009-P06009, 2021/06/01
  • α-Emitting cancer therapy using 211 At-AAMT targeting LAT1., Kazuko Kaneda-Nakashima,ZiJian Zhang,Yoshiyuki Manabe,Atsushi Shimoyama,Kazuya Kabayama,Tadashi Watabe,Yoshikatsu Kanai,Kazuhiro Ooe,Atsushi Toyoshima,Yoshifumi Shirakami,Takashi Yoshimura,Mitsuhiro Fukuda,Jun Hatazawa,Takashi Nakano,Koichi Fukase,Atsushi Shinohara, Cancer science, Vol. 112, No. 3, p. 1132-1140, 2020/12/05
  • Development of high-resolution YAP(Ce) x-ray camera for the imaging of astatine-211(At-211) in small animals, Kouhei Nakanishi,Seiichi Yamamoto,Tadashi Watabe,Kazuko Kaneda-Nakashima,Yoshifumi Shirakami,Kazuhiro Ooe,Atsushi Toyoshima,Atsushi Shinohara,Takahiro Teramoto,Jun Hatazawa,Kei Kamada,Akira Yoshikawa, Medical Physics, Vol. 47, No. 11, p. 5739-5748, 2020/11
  • Preclinical Evaluation of Radiation-Induced Toxicity in Targeted Alpha Therapy Using [<sup>211</sup>At] NaAt in Mice: A Revisit, Yuwei Liu,Tadashi Watabe,Kazuko Kaneda-Nakashima,Kazuhiro Ooe,Yoshifumi Shirakami,Atsushi Toyoshima,Eku Shimosegawa,Takashi Nakano,Atsushi Shinohara,Jun Hatazawa, Translational Oncology, Vol. 13, No. 4, p. 100757-100757, 2020/04
  • Targeted alpha therapy using astatine (<sup>211</sup>At)-labeled phenylalanine: A preclinical study in glioma bearing mice, Tadashi Watabe,Kazuko Kaneda-Nakashima,Yoshifumi Shirakami,Yuwei Liu,Kazuhiro Ooe,Takahiro Teramoto,Atsushi Toyoshima,Eku Shimosegawa,Takashi Nakano,Yoshikatsu Kanai,Atsushi Shinohara,Jun Hatazawa, Oncotarget, Vol. 11, No. 15, p. 1388-1398, 2020/04
  • Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: <sup>64</sup>Cu- and <sup>225</sup>Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models, Tadashi Watabe,Yuwei Liu,Kazuko Kaneda-Nakashima,Yoshifumi Shirakami,Thomas Lindner,Kazuhiro Ooe,Atsushi Toyoshima,Kojiro Nagata,Eku Shimosegawa,Uwe Haberkorn,Clemens Kratochwil,Atsushi Shinohara,Frederik Giesel,Jun Hatazawa, Journal of nuclear medicine : official publication, Society of Nuclear Medicine, Vol. 61, No. 4, p. 563-569, 2020/04
  • 甲状腺癌に対する標的アルファ線治療 担癌モデルにおけるアスタチン化ナトリウムの治療効果の検討, 渡部 直史,兼田 加珠子,劉 雨薇,白神 宣史,大江 一弘,豊嶋 厚史,下瀬川 恵久,福田 光宏,篠原 厚,畑澤 順, 核医学, (一社)日本核医学会, Vol. 56, No. Suppl., p. S146-S146, 2019/10
  • Dissolution of dry distilled At-211 th non-toxic aqueous solutions, Ooe Kazuhiro,Watabe Tadashi,Shirakami Yoshifumi,Ichimura Soichiro,Obata Honoka,Ikeda Takumi,Zhang Zi Jian,Nagata Kojiro,Toyoshima Atsushi,Yoshimura Takashi,Shinohara Atsushi,Hatazawa Jun, JOURNAL OF NUCLEAR MEDICINE, Vol. 60, 2019/05/01
  • Radiohalogenated Neopentyl Derivatives: A Novel Scaffold for Radioiodinated and astatinated Compounds of High Stability to In Vivo Dehalogenation, Hiroyuki Suzuki,Hiroshi Tanaka,Nana Washiya,Maho Tatsuta,Yui Sato,Yuta Kaizuka,Shigeki Watanabe,Tomoya Uehara,Noriko Ishioka,Yoshifumi Shirakami,Kazuhiro Ooe,Atsushi Toyoshima,Tadashi Watabe,Jun Hatazawa,Yasushi Arano, Journal of Medical Imaging and Radiation Sciences, Elsevier {BV}, Vol. 50, No. 1, p. S22-S23, 2019/03
  • Activities of the Consortium for Medicine, Chemistry, and Physics at Osaka University, Kazuya Kabayama,Kazuko Kaneda,Atsushi Shinohara,Yoshifumi Shirakami,Tadashi Watabe,Zijian Zhang,Atsushi Toyoshima,Takashi Yoshimura,Yoshiyuki Manabe,Atsushi Shimoyama,Koichi Fukase, Journal of Medical Imaging and Radiation Sciences, Elsevier BV, Vol. 50, No. 1, p. S40-S40, 2019/03
  • Enhancement of <sup>211</sup>At uptake via the sodium iodide symporter by the addition of ascorbic acid in targeted A-therapy of thyroid cancer, Tadashi Watabe,Kazuko Kaneda-Nakashima,Yuwei Liu,Yoshifumi Shirakami,Kazuhiro Ooe,Atsushi Toyoshima,Eku Shimosegawa,Mitsuhiro Fukuda,Atsushi Shinohara,Jun Hatazawa, Journal of Nuclear Medicine, Vol. 60, No. 9, p. 1301-1307, 2019
  • 甲状腺へのAt-211取り込みの亢進 ラットにおけるSPECT研究(Enhancement of At-211 uptake in the thyroid gland: SPECT study in rats), Liu Yuwei,渡部 直史,兼田 加珠子[中島],白神 宜史,豊嶋 厚史,巽 光朗,下瀬川 恵久,福田 光宏,篠原 厚,畑澤 順, 核医学, (一社)日本核医学会, Vol. 55, No. Suppl., p. S173-S173, 2018/11
  • Energy Failure Hypothesis for Takotsubo Cardiomyopathy, Yoshifumi Shirakami, Annals of Nuclear Cardiology, 2017
  • Preclinical properties and human in vivo assessment of <sup>123</sup>I-ABC577 as a novel SPECT agent for imaging amyloid-β, Yoshifumi Maya,Yuki Okumura,Ryohei Kobayashi,Takako Onishi,Yoshinari Shoyama,Olivier Barret,David Alagille,Danna Jennings,Kenneth Marek,John Seibyl,Gilles Tamagnan,Akihiro Tanaka,Yoshifumi Shirakami, Brain, Vol. 139, No. 1, p. 193-203, 2016/01/01
  • [<sup>14</sup>C]Fluciclovine (alias anti-[<sup>14</sup>C]FACBC) uptake and ASCT2 expression in castration-resistant prostate cancer cells, Masahiro Ono,Shuntaro Oka,Hiroyuki Okudaira,Takeo Nakanishi,Atsushi Mizokami,Masato Kobayashi,David M. Schuster,Mark M. Goodman,Yoshifumi Shirakami,Keiichi Kawai, Nuclear Medicine and Biology, Vol. 42, No. 11, p. 887-892, 2015/11
  • Evaluation of trans-1-amino-3-<sup>18</sup>F-fluorocyclobutanecarboxylic acid accumulation in low-grade glioma in chemically induced rat models: PET and autoradiography compared with morphological images and histopathological findings, Yoshihiro Doi,Masaru Kanagawa,Yoshifumi Maya,Akihiro Tanaka,Shuntaro Oka,Norihito Nakata,Masahito Toyama,Hiroki Matsumoto,Yoshifumi Shirakami, Nuclear Medicine and Biology, Vol. 42, No. 8, p. 664-672, 2015/08/01
  • Corrigendum to "Kinetic analyses of trans-1-amino-3-[<sup>18</sup>F]fluorocyclobutanecarboxylic acid transport in Xenopus laevis oocytes expressing human ASCT2 and SNAT2" [Nucl. Med. Biol, 2013, 40, 670-675], doi: 10.1016/j.nucmedbio.2013.03.009, Hiroyuki Okudaira,Takeo Nakanishi,Shuntaro Oka,Masato Kobayashi,Hiroshi Tamagami,David M. Schuster,Mark M. Goodman,Yoshifumi Shirakami,Ikumi Tamai,Keiichi Kawai, Nuclear Medicine and Biology, Elsevier Inc., Vol. 42, No. 5, p. 513-514, 2015/05/01
  • Kinetic analyses of trans-1-amino-3-[F-18]fluorocyclobutanecarboxylic acid transport in Xenopus laevis oocytes expressing human ASCT2 and SNAT2 (vol 40, pg 670, 2013), Hiroyuki Okudaira,Takeo Nakanishi,Shuntaro Oka,Masato Kobayashi,Hiroshi Tamagami,David M. Schuster,Mark M. Goodman,Yoshifumi Shirakami,Ikumi Tamai,Keiichi Kawai, NUCLEAR MEDICINE AND BIOLOGY, ELSEVIER SCIENCE INC, Vol. 42, No. 5, p. 513-514, 2015/05
  • Radioactive Iodine, Yoshifumi Shirakami, Iodine Chemistry and Applications, Wiley Blackwell, Vol. 9781118466292, p. 603-624, 2014/11/24
  • Accumulation of Trans-1-Amino-3-[<sup>18</sup>F]Fluorocyclobutanecarboxylic Acid in Prostate Cancer due to Androgen-Induced Expression of Amino Acid Transporters, Hiroyuki Okudaira,Shuntaro Oka,Masahiro Ono,Takeo Nakanishi,David M. Schuster,Masato Kobayashi,Mark M. Goodman,Ikumi Tamai,Keiichi Kawai,Yoshifumi Shirakami, Molecular Imaging and Biology, Vol. 16, No. 6, p. 756-764, 2014/11/18
  • Comparison of trans-1-amino-3-[<sup>18</sup>F]fluorocyclobutanecarboxylic acid (anti-[<sup>18</sup>F]FACBC) accumulation in lymph node prostate cancer metastasis and lymphadenitis in rats, Masaru Kanagawa,Yoshihiro Doi,Shuntaro Oka,Ryohei Kobayashi,Norihito Nakata,Masahito Toyama,Yoshifumi Shirakami, Nuclear Medicine and Biology, Vol. 41, No. 7, p. 545-551, 2014/08
  • Differences in transport mechanisms of trans-1-amino-3-[ <sup>18</sup>F]fluorocyclobutanecarboxylic acid in inflammation, prostate cancer, and glioma cells: Comparison with L-[methyl-<sup>11</sup>C]methionine and 2-deoxy-2-[<sup>18</sup>F]fluoro-D-glucose, Shuntaro Oka,Hiroyuki Okudaira,Masahiro Ono,David M. Schuster,Mark M. Goodman,Keiichi Kawai,Yoshifumi Shirakami, Molecular Imaging and Biology, Vol. 16, No. 3, p. 322-329, 2014/06
  • Comparative evaluation of transport mechanisms of trans-1-amino-3-[ <sup>18</sup>F]fluorocyclobutanecarboxylic acid and l-[methyl- <sup>11</sup>C]methionine in human glioma cell lines, Masahiro Ono,Shuntaro Oka,Hiroyuki Okudaira,David M. Schuster,Mark M. Goodman,Keiichi Kawai,Yoshifumi Shirakami, Brain Research, Vol. 1535, p. 24-37, 2013/10/16
  • Kinetic analyses of trans-1-amino-3-[<sup>18</sup>F]fluorocyclobutanecarboxylic acid transport in Xenopus laevis oocytes expressing human ASCT2 and SNAT2, Hiroyuki Okudaira,Takeo Nakanishi,Shuntaro Oka,Masato Kobayashi,Hiroshi Tamagami,David M. Schuster,Mark M. Goodman,Yoshifumi Shirakami,Ikumi Tamai,Keiichi Kawai, Nuclear Medicine and Biology, Vol. 40, No. 5, p. 670-675, 2013/07
  • Transport mechanisms of trans-1-amino-3-fluoro[1- <sup>14</sup>C]cyclobutanecarboxylic acid in prostate cancer cells, Shuntaro Oka,Hiroyuki Okudaira,Yasunori Yoshida,David M. Schuster,Mark M. Goodman,Yoshifumi Shirakami, Nuclear Medicine and Biology, Vol. 39, No. 1, p. 109-119, 2012/01
  • Uptake of FDG (2-fluoro-2-deoxy-D-glucose) as a tumor imaging agent into erythrocytes and accumulation of FDG in tumor cells, Yoshihito Minosako,Masahiro Nemoto,Sento Ino,Yoshifumi Shirakami,Miki Kurami, Kakuigaku, Vol. 40, No. 1, p. 23-30, 2003
  • Kinetics of a putative hypoxic tracer, <sup>99m</sup>Tc-HL91, in normoxic, hypoxic, ischemic, and stunned myocardium, Kenichi Imahashi,Kenichi Morishita,Hideo Kusuoka,Yoshihiro Yamamichi,Shinji Hasegawa,Katsuji Hashimoto,Yoshifumi Shirakami,Makoto Kato-Azuma,Tsunehiko Nishimura, Journal of Nuclear Medicine, Vol. 41, No. 6, p. 1102-1107, 2000/06
  • Development of <sup>18</sup>F-FDG ([F-18]-2-fluoro-2-deoxy-D-glucose) injection for imaging of tumor reflecting glucose metabolism - Results of preclinical studies, Sento Ino,T. Shimada,M. Kanagawa,N. Suzuki,S. Kondo,Y. Shirakami,O. Ito,M. Kato-Azuma, Kakuigaku, Japanese Society of Nuclear Medicine, Vol. 36, No. 5, p. 467-476, 1999
  • Direct labeling of macroaggregated albumin with indium-111-chloride using acetate buffer, Naoyuki Watanabe,Yoshifumi Shirakami,Katsumi Tomiyoshi,Noboru Oriuchi,Tsuneo Hirano,Tetsuya Higuchi,Tomio Inoue,Keigo Endo, Journal of Nuclear Medicine, Vol. 38, No. 10, p. 1590-1592, 1997/10
  • Indirect labeling of macroaggregated albumin with Indium-111 via diethylenetriaminepentaacetic acid, Naoyuki Watanabe,Yoshifumi Shirakami,Katsumi Tomiyoshi,Noboru Oriuchi,Tsuneo Hirano,Masashi Yukihiro,Tomio Inoue,Keigo Endo, Nuclear Medicine and Biology, Elsevier Inc., Vol. 23, No. 5, p. 595-598, 1996/07
  • Metabolism of iodine-123-BMIPP in perfused rat hearts, Y. Yamamichi,H. Kusuoka,K. Morishita,Y. Shirakami,M. Kurami,K. Okano,O. Itoh,T. Nishimura, Journal of Nuclear Medicine, Vol. 36, No. 6, p. 1043-1050, 1995
  • Scavenger Effects on Recoil-Tritium Reactions with 5,10,15,20-Tetraphenylporphyrin, G. Izawa,K. Shirahashi,Y. Murano,K. Yoshihara, Radiochimica Acta, Vol. 46, No. 4, p. 191-196, 1989/04
  • Metabolic products of technetium human serum albumin D (<sup>99m</sup>Tc) in the human blood and urine, Y. Shirakami,Y. Matsumoto,K. Yoshinari,K. Minami,M. Kurami,J. Ishimura,M. Fukuchi, Kakuigaku, Vol. 26, No. 2, p. 279-282, 1989
  • Development of Tc-99m-DTPA-HSA as a new blood pool scanning agent, Y. Shirakami,Y. Matsumoto,Y. Yamauchi,M. Kurami,N. Ueda,M. Hazue, Kakuigaku, Vol. 24, No. 4, p. 475-478, 1987
  • A rapid preparation method for <sup>39</sup>Cl-labelled alkyl chlorides, Masuo Yagi,Yoshifumi Murano,Gunzo Izawa,Kazuyoshi Masumoto, The International Journal Of Applied Radiation And Isotopes, Vol. 36, No. 1, p. 69-73, 1985/01
  • Reactions of Recoil Tritium with Heterocyclic Compounds: Pyrroles and Uracil, Yoshifumi Murano,Jun Akimoto,Kenji Yoshihara, Radiochimica Acta, Vol. 38, No. 1, p. 11-14, 1985/01
  • Tritium Exchange Reactions of Water with Pyrrole and 2, 5-Dimethylpyrrole: II. Role of Hydrogen Bonding in Tritium Transfer Reaction in Pyrrole and its MO Calculation, Yoshifumi Murano,Kenji Yoshihara, Radiochimica Acta, Vol. 37, No. 1, p. 37-40, 1984/07
  • Tritium Exchange Reactions of Water with Pyrrole and 2, 5-Dimethylpyrrole. I. Tritium Fractionation Factor and Effect of Hydrogen Bonding, Y. Murano,J. Akimoto,K. Yoshihara, Radiochimica Acta, Vol. 36, No. 3, p. 145-148, 1984/05
  • Radio-liquid chromatogrphy for tritium labelled organic compounds using CaF<inf>2</inf>/Eu/ scintillator, K. Shirahashi,G. Izawa,Y. Murano,Y. Muramastu,K. Yoshihara, Journal of Radioanalytical and Nuclear Chemistry Letters, Vol. 86, No. 1, p. 1-9, 1984/04
  • Rapid and high-yield synthesis of carrier-free <sup>18</sup>F-labelled alkyl flourides, Masuo Yagi,Yoshifumi Murano,Gunzo Izawa, The International Journal Of Applied Radiation And Isotopes, Vol. 33, No. 12, p. 1335-1339, 1982/12
  • Formation of LiHe<sup>+</sup> by gas-phase reaction of LiCl with He, Y. Murano,G. Izawa,K. Yoshihara,M. Takahashi,M. Kishimoto,S. Suzuki, International Journal of Mass Spectrometry and Ion Physics, Vol. 41, No. 3, p. 179-183, 1982/01

Misc.

  • 進行がんや手術困難例に対する核医学治療薬の現状と新規治療薬の開発—Development of nuclear medicine for targeting alpha therapy to cancer, 兼田(中島) 加珠子,樺山 一哉,白神 宜史,渡部 直史,豊嶋 厚史,深瀬 浩一, 臨床免疫・アレルギー科 = Clinical immunology & allergology / 臨床免疫・アレルギー科編集委員会 編, 科学評論社, Vol. 79, No. 3, p. 348-352, 2023/03
  • Activities of Targeted Alpha Therapy at Osaka University, Kabayama Kazuya,Shirakami Yoshifumi,Kaneda Kazuko,Watabe Tadashi,Toyoshima Atsushi, MEDCHEM NEWS, The Pharmaceutical Society of Japan, Vol. 32, No. 2, p. 93-98, 2022/05/01
  • Synthetic study of At-211 labeled cancer targeting amino acids,, Zihao Qiu,Yoshifumi Shirakami,Kazuko Kaneda,Yuichiro Kadonaga,Kazuhiro Ooe,Atsushi Toyoshima,Atsushi Shinohara,Koichi Fukase, 2021/03
  • アスタチンを用いた難治性甲状腺がんに対するアルファ線核医学治療, 渡部 直史,兼田 加珠子,白神 宜史,大江 一弘,豊嶋 厚史,篠原 厚, アイソトープ・放射線研究発表会, 公益社団法人 日本アイソトープ協会, Vol. 1, 2021
  • アスタト-脱ボロン酸反応による<sup>211</sup>At標識αメチルチロシンの製造と生物活性に関する研究, 白神宜史,白神宜史,白神宜史,兼田加珠子,兼田加珠子,渡部直史,渡部直史,大江一弘,大江一弘,角永悠一郎,仲定宏,川上厚子,山中敏夫,近藤裕,豊嶋厚史,深瀬浩一, 核医学(Web), Vol. 58, No. Supplement, 2021
  • Preparation of 211At-NaAt with reducing agent and analysis with ion-pair chromatography, Shirakami Y,Knaeda-Nakajima K,Watabe T,Ooe K,Liu W,Teramoto T,Toyoshima A,Shinohara A,Nakano T,Shimosegawa E,Hatazawa, Vol. 57, No. Supplement, 2020/11
  • Targeted alpha therapy using astatine (211At)-labeled phenylalanine: a preclinical study in glioma xenograft mice, Tadashi Watabe,Kazuko Kaneda-Nakashima,Yoshifumi Shirakami,Yuwei Liu,Kazuhiro Ooe,Atsushi Toyoshima,Eku Shimosegawa,Takashi Nakano,Yoshikatsu Kanai,Atsushi Shinohara,Jun Hatazawa, 2020/11
  • Studies on cyclotron production and chemical separation of Ag-111 from Pd target., Kazuhiro Ooe,Tadashi Watabe,Yoshifumi Shirakami,Daiki Mori,Takuya Yokokita,Yukiko Komori,Hiromitsu Haba,Jun Hatazawa, Vol. 57, No. Supplement, 2020/11
  • Development of targeted alpha therapy using Actinium-225, Yoshifumi Shirakami, GIMRT Joint International Symposium on Radiation Effects in Materials and Actinide Science (GIMRT-REMAS2020), 2020/10
  • Preparation of [<sup>211</sup>At] Pure Sodium Astatide (NaAt) for Nuclear Medicine Application, 白神宜史,白神宜史,大江一弘,大江一弘,兼田加珠子,兼田加珠子,寺本高啓,渡部直史,渡部直史,豊嶋厚史,豊嶋厚史,篠原厚,篠原厚,畑澤順,畑澤順, 日本放射化学会討論会(Web), Vol. 64th, 2020/09
  • Preclinical evaluation of radiation-induced toxicity in targeted alpha therapy using [211At] NaAt in mice: a revisit, Liu Yuwei,Tadashi Watabe,Kazuko Kaneda-Nakashima,Kazuhiro Ooe,Yoshifumi Shirakami,Atsushi Toyoshima,Eku Shimosegawa,Takashi Nakano,Atsushi Shinohara,Jun Hatazawa, J Nucl Med, Vol. 61, No. Supplement 1, 2020/06
  • Metabolic studies of astatine- and radioiodine-labeled neopentyl derivatives, Yuta Kaizuka,Hiroyuki Suzuki,Hiroshi Tanaka,Nana Washiya,Maho Tatsuta,Yui,Sato, Shigeki,Watanabe, Noriko,Ishioka,Yoshifumi Shirakami,Kazuhiro Ooe,Atsushi Toyoshima,Tadashi Watabe,Jun Hatazawa,Yasushi Arano,Tomoya Uehara, J Nucl Med 2020 (May); 61, (supplement 1): 1100., Vol. 61, No. Supplement 1, 2020/06
  • Targeted alpha therapy using astatine (211At)-labeled phenylalanine: a preclinical study in glioma xenograft mice, Tadashi Watabe,Kazuko Kaneda-Nakashima,Yoshifumi Shirakami,Yuwei Liu,Kazuhiro, Ooe,Atsushi,Toyoshima, Eku,Shimosegawa,Takashi Nakano,Yoshikatsu Kanai,Atsushi, Shinohara,Jun Hatazawa, J Nucl Med 2020, Vol. 61, No. Supplment 1, 2020/06
  • Development of high-resolution YAP(Ce) X-ray camera for the imaging of astatine-211 in small animals, 中西恒平,山本誠一,渡部直史,兼田加珠子,白神宜史,大江一弘,豊嶋厚史,篠原厚,寺本高啓,畑澤順, JSMI Report, Vol. 13, No. 2, 2020
  • α線核医学治療の新たな展開, 渡部直史,白神宜史,篠原厚, Isotope News (Web), No. 771, 2020
  • アルファ線放出核種アスタチンを用いた新しい甲状腺癌治療, 渡部直史,渡部直史,兼田加珠子,劉雨薇,白神宜史,大江一弘,大江一弘,豊嶋厚史,下瀬川恵久,下瀬川恵久,下瀬川恵久,篠原厚,篠原厚, 日本内分泌学会雑誌, Vol. 96, No. 4 (Web), 2020
  • Production and chemical purification of Ag-111 toward nuclear medical application, 大江一弘,大江一弘,渡部直史,渡部直史,白神宜史,森大輝,横北卓也,小森有希子,羽場宏光,畑澤順,畑澤順, 日本放射化学会討論会(Web), Vol. 64th, 2020
  • アスタチン標識フェニルアラニンを用いたα線核医学治療:脳腫瘍担癌マウスにおける検討, 渡部直史,渡部直史,兼田加珠子,白神宜史,劉雨薇,大江一弘,大江一弘,寺本高啓,豊嶋厚史,下瀬川恵久,中野貴志,金井好克,畑澤順, 核医学(Web), Vol. 57, No. Supplement, 2020
  • Investigation of drug for <sup>211</sup>At-labeled nuclear medicine targeting to cancer specific amino acid transporter., 兼田加珠子,兼田加珠子,白神宜史,白神宜史,大江一弘,大江一弘,寺本高啓,渡部直史,渡部直史,下山敦史,下山敦史,真鍋良幸,真鍋良幸,樺山一哉,樺山一哉,豊嶋厚史,豊嶋厚史,豊嶋厚史,深瀬浩一,深瀬浩一,篠原厚,篠原厚, 日本放射化学会討論会(Web), Vol. 64th, 2020
  • Development of radiation imaging systems with discrimination capability of the types of radiations and application to alpha particle distribution measurements, 山本誠一,渡部直史,兼田加珠子,白神宣史,大江一弘,篠原厚,豊嶋厚史,畑澤順, JSMI Report, Vol. 12, No. 2, 2019
  • Investigation into the specificity of borono-astatine exchange reaction in aqueous solution., 尾幡穂乃香,白神宜史,兼田加珠子,大江一弘,永田光知郎,寺本高啓,市村聡一朗,中川創太,吉村崇,豊嶋厚史,篠原厚,篠原厚, 日本放射化学会討論会(Web), Vol. 63rd, 2019
  • Establishment of novel targeted alpha-radionuclide medicine, Kaneda Kazuko,Fukuda Mitsuhiro,Kanai Yoshikatsu,Hatazawaj Jun,Nakano Takashi,Fukase Koichi,Shinohara Atsushi,Zhang Zijian,Shirakami Norifumi,Watabe Tadashi,Shimoyama Atsushi,Manabey Yoshiyuki,Kabayama Kazuya,Toyoshima Atsushi,Yoshimura Takashi, Proceedings for Annual Meeting of The Japanese Pharmacological Society, Japanese Pharmacological Society, Vol. 92, No. 0, p. 3-P-109, 2019
  • アミノ酸トランスポーターLAT1を標的とするα線がんミサイル療法の開発, 兼田 加珠子,張 子見,真鍋 良幸,下山 敦史,樺山 一哉,白神 宜史,金井 好克,畑澤 順,深瀬 浩一,篠原 厚, 日本生化学会大会プログラム・講演要旨集, (公社)日本生化学会, Vol. 91回, p. [2P-272], 2018/09
  • Enhancement of At-211 uptake in the thyroid gland- SPECT study in rats, Yuwei Liu,Tadashi Watabe,Kazuko Kaneda-Nakashima,Yoshifumi Shirakami,Atsushi Toyoshima,Mitsuaki Tatsumi,Eku Shimosegawa,Mitsuhiro Fukuda,Atsushi Shinohara,Jun Hatazawa, JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, Vol. 59, 2018/05
  • Species difference of astatine-211 uptakes in the whole body distribution: preclinical study using treated At-solution, Tadashi Watabe,Kazuko Kaneda-Nakashima,Yuwei Liu,Yoshifumi Shirakami,Atsushi Toyoshima,Mitsuaki Tatsumi,Eku Shimosegawa,Mitsuhiro Fukuda,Atsushi Shinohara,Jun Hatazawa, JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, Vol. 59, 2018/05
  • TRANSPORT MECHANISM OF THE AMINO ACID POSITRON EMISSION TOMOGRAPHY TRACER [F-18] FLUCICLOVINE AND ITS APPLICATION TO GLIOMA DIAGNOSIS, Masahiro Ono,Yoshihiro Doi,Shuntaro Oka,Hiroyuki Okudaira,David M. Schuster,Mark M. Goodman,Hiroki Matsumoto,Keiichi Kawai,Yoshifumi Shirakami, DRUG METABOLISM REVIEWS, TAYLOR & FRANCIS LTD, Vol. 47, p. 249-249, 2015/11
  • 前立腺癌へのtrans-1-amino-3-18F-fluorocyclobutanecarboxylic acid(anti-18F-FACBC)の輸送機序, 奥平宏之,岡俊太郎,中西猛夫,小林正和,シャスター デービッド,グッドマン マーク,玉井郁巳,川井恵一,白神宜史, 日本DDS学会学術集会プログラム予稿集, Vol. 30th, 2014
  • アルツハイマー病患者及び健康成人における新規I-123標識SPECT用Aβイメージングプローブの有効性評価, 田中昭広,大西崇子,白神宜史, 核医学, Vol. 51, No. 3, 2014
  • 新規アミロイドイメージング用プローブの探索研究-イミダゾピリジン-フェノール誘導体の合成及び基礎評価, 大西崇子,谷藤樹之,田中昭広,玉上浩,白神宜史, 核医学, Vol. 45, No. 3, 2008
  • Metabolic imaging of human body by radiohalogenated molecules, SHIRAKAMI Yoshifumi, Vol. 13, No. 4, p. 212-213, 2002/12/30
  • Pharmacokinetics of radioiodinated fatty acid myocardial imaging agents in animal models and human studies, Jr Knapp,J. Kropp,P. R. Franken,F. C. Visser,G. W. Sloof,M. Eisenhut,Y. Yamamichi,Y. Shirakami,H. Kusuoka,T. Nishimura, Quarterly Journal of Nuclear Medicine, Vol. 40, No. 3, p. 252-269, 1996

Publications

  • NAS/COMMENTARIES:No.27, 編集：一般財団法人日本原子力産業協会 原子力システム研究懇談会 有限会社トック（東京）, 2023/03
  • Iodine chemistry and applications, Shirakami Yoshifumi, Wiley & Sons Inc, 2014/11

Industrial Property Rights

  • アスタチン溶液及びその製造方法, 白神 宜史, 特許7237366, 特願2017-255109, 出願日:2017/12/29, 登録日:2023/03/03
  • 放射標識されたアリール化合物の製造方法, 白神 宜史, 特許7232527, 特願2017-151632, 出願日:2017/08/04, 登録日:2023/02/22
  • アスタチン溶液およびその製造方法, 白神宜史,畑澤順,下瀬川恵久渡部直史,篠原厚,兼田加珠子, 特願2023-025287, 出願日:2023/02/21
  • 放射標識されたFAPIα親和性化合物およびその用途, 白神宜史,角永悠一郎、兼田加珠子,渡部直史, 下山敦史、麻生彩佳,深瀬浩一,吉矢拓, 特願2022-26194, 出願日:2022/02/22
  • 放射標識された化合物及びその用途, 白神宜史,兼田加珠子,角永悠一郎,渡部直史,豊嶋厚史,深瀬浩一,篠原厚,山中敏夫,近藤裕, 特願2021-125774, 出願日:2021/07/30
  • ボロン酸化合物およびその製造方法, 白神宜史,兼田加珠子,渡部直史,角永悠一郎,豊嶋厚史,深瀬浩一,篠原厚,山中敏夫,近藤裕, 特願2021-052352, 出願日:2021/03/25
  • 211At標識アミノ酸誘導体を含む医薬組成物及びその製造方法, 白神 宜史, 特願2018-048562, 出願日:2018/03/15

Presentations

  • Synthesis and Preclinical Evaluation of 225Ac-PSMA-617 for Targeted Alpha Therapy in Mice with Prostate Cancer., Yoshifumi Shirakami白神宜史,渡部直史,兼田加珠子,角永悠一郎,大江一弘,豊嶋厚史,永田光知郎,吉村崇,塚田和明,白崎謙次,菊永英寿,J Cardinale,F Giesel,神野直哉,深瀬浩一, IMR-Oarai & Oarai-Alpha Workshop 2022/09/28-30, 2022/09/30
  • . 211At標識PSMA誘導体による前立腺がんα線核医学治療, 白神宜史,角永悠一郞,渡部直史,兼田加珠子,神野直哉,大江一弘,羽場宏光,豊嶋厚史,深瀬浩一, 第5回日本核医学会分科会 放射性薬品科学研究会 第21回放射性医薬品・画像診断薬研究会, 2022/09/19
  • 核医学利用に向けたCe-141の加速器製造と分離精製の検討., 大江一弘,渡部直史,白神宜史,南部明弘,羽場宏光,畑澤順, 日本放射化学会第66回討論会 2022.9.15-17（東京）, 2022/09/15
  • 難治性甲状腺がんに対するアスタチンを用いた医師主導治験, 渡部直史,仲定宏,大江一弘,豊嶋厚史,王洋,羽場宏光,白神宜史, 第59回アイソトープ・放射線研究発表会（オンライン、2022年7月6-8日）, 2022/07/06
  • がんの創薬研究：PET画像診断からα線核医学治療へ., 白神宜史, ギルソン社ピペットマン生誕50周年記念 研究フォーラム, 2022/06/16
  • Targeted alpha therapy using astatine (211At)-labeled PSMA5: a preclinical evaluation as a new novel compound, Tadashi Watabe,Kazuo Kaneda,Yoshifumi Shirakami,Yuichiro Kadonaga,Kazuhiro Ooe,Yang Wang,Hiromitsu Haba,Atsushi Toyoshima,Koichi Fukase, SNMMI2022, 2022/06/12
  • Synthesis and preclinical evaluation of PSMA ligands labeled with astatine-211, Yoshifumi Shirakami,Tadashi Watabe,Yuichiro Kadonaga,Kazuo Kaneda,Kazuhiro Ooe,Yang Wang,Hiromitsu Haba,Atsushi Toyoshima,Koichi Fukase, SNMMI20226, 2022/06/12
  • Manufacturing of [211At]NaAt for the first‑in‑human clinical trial of targeted alpha therapy for differentiated thyroid cancer at Osaka University Hospital, Kazuhiro Ooe,Sadahiro Naka,Yoshifumi Shirakami,Eku Shimosegawa,Hiroki Kato,Mitsuaki Tatsumi,Hiromitsu Haba,Atsushi Toyoshima,Tadashi Watabe, SNMMI2023, 2022/06/12
  • At-211-labeled L-tyrosine derivatives via neopentyl scaffold for targeted α-therapy, Yuta Kaizuka,Hiroyuki Suzuki,Tadashi Watabe,Yoshifumi Shirakami,Kazuhiro Ooe,Takahiro Teramoto,Atsushi Toyoshima,Tomoya Uehara, Int Symp Radiopharm Sci 2022, 2022/05/29
  • Theranostics targeting fibroblast activation protein, Tadashi Watabe,Yuwei Liu,Kazuko Kaneda-Nakashima,Yoshifumi Shirakami,Sadahiro Naka,Kazuhiro Ooe,Atsushi Toyoshima,Kojiro Nagata,Frederik Giesel, 2022/05/26
  • The comparison of therapeutic effect between [211At]NaAt and [131I]NaI: preclinical study using mice xenograft model of differentiated thyroid cancer., Yuwei Liu,Tadashi Watabe,Kazuko Kaneda-Nakashima,Kazuhiro Ooe,Yoshifumi Shirakami,Atsushi Toyoshima,Eku Shimosegawa,Takashi Nakano,Atsushi Shinohara,Jun Hatazawa, J Nucl Med 2021 (May 1); 62, Suppl 1, 98, 2021/05/01
  • Synthesis;evaluation of;At-labeled FAPIs for;targeted alpha therapy, 2022/03/23
  • Performance evaluation of 18F-FAPI-74 in the FAP expressing pancreatic cancer., 劉雨薇,Tadashi Watabe,Sadahiro Naka,Yoshifumi Shirakami,Thomas Linder,Kazuhiro Ooe,Eku Shimosegawa,Uwe Haberkorn,Frederik Giesel,Jun Hatazawa, 第61回日本核医学会学術総会, 2021/11/04
  • Enhanced therapeutic effect with repeated administration of [ 211At]NaAt in mice, 劉雨薇,Tadashi Watabe,Kazuko Kaneda-Nakashima,Kazuhiro Ooe,Yoshifumi Shirakami,Atsushi Toyoshima,Eku,Shimosegawa,Takashi Nakano,Atsushi Shinohara,Jun Hatazawa, 第61回日本核医学会学術総会, 2021/11/04
  • アスタチン（[ 211At]NaAt）の治験開始に必要な拡張型単回投与毒性試験について, 渡部直史,兼田加珠子,大江一弘,劉雨薇,栗本健太,豊嶋厚史,篠原厚,白神史, 第61回日本核医学会学術総会. 2021/11/4-6, 名古屋, 2021/11/04
  • がんのラジオセラノスティクスを目的とした放射性ヨウ素/アスタチン-211標識チロシン誘導体の開発, 貝塚祐太,鈴木博元,渡部直史,白神宜史,大江一弘,寺本 高啓,豊嶋厚史,畑澤順,上原知也, 第61回日本核医学会学術総会. 2021/11/4-6, 名古屋, 2021/11/04
  • アスタト－脱ボロン酸反応による211At標識αメチルチロシンの製造と生物活性に関する研究., 白神宜史,兼田加珠子,渡部直史,大江一弘,角永悠一郎,仲定宏,川上厚子,中山敏夫,近藤裕,豊嶋厚史,深瀬浩一, 第61回日本核医学会学術総会. 2021/11/4-6, 名古屋, 2021/11/04
  • 乾式分離と純水を用いた溶解によるアスタチン211の分離精製, 大江一弘,豊嶋厚史,寺本高啓,永田光知郎,床井健運,中川創太,渡部直史,白神宜史,吉村崇,篠原厚,畑澤順, 第61回日本核医学会学術総会, 2021/11/04
  • Estimated absorbed;dose in human after intravenous administration of;At]NaAt for the FIH clinical trial of;targeted alpha therapy, Tadashi Watabe,Tatsuhiko Sato,Kazuko Kaneda-Nakashima,Kazuhiro Ooe,Yuwei Liu,Kenta Kurimoto,Atsushi Toyoshima,Atsushi Shinohara,Yoshifumi Shirakami, Eur J Nuc Med 2021: 48: S41-42. Eur Assoc Nucle Med Oct 20-23, 2021, 2021/10/20
  • アクチニウム(225Ac)標識薬剤の製造研究, 白神宜史,渡部直史,兼田加珠子,角永悠一郎,川上厚子,劉雨薇,大江一弘,豊嶋厚史,永田光知郎,吉村崇,塚田和明,白崎謙次,菊永英寿,F Giese,深瀬浩一, 大洗・アルファ合同研究, 2021/10/01
  • 225Ac標識FAPIの合成と品質に関する検討, 白神宜史,渡部直史,兼田加珠子,角永悠一郎,川上厚子,劉慈雨,大江一弘,豊嶋厚史,永田光知郎,吉村崇,深瀬浩一, 第4回日本核医学会分科会放射性薬品科学研究会 第20回放射性医薬品画像診断薬研究会, 2021/09/25
  • ボロン酸を置換基とする[211At]標識アリール化合物の合成, 白神宜史,兼田加珠子,渡部直史,大江一弘,劉雨薇,川上厚子,寺本高啓,羽場宏光,王洋,豊嶋厚史,深瀬浩一, 新学術領域研究;研究領域提案型;学術研究支援基盤形成;短寿命RI供給プラットフォーム成果報告会兼RI利用, 2021/07/19
  • アスタチンを用いた難治性甲状腺がんに対するアルファ線核医学治療, 渡部 直史,兼田 加珠子,白神宜史,大江一弘,豊嶋厚史,篠原厚, 第58回アイソトープ放射線研究発表会, 2021/07/09
  • アスタチンの医師主導治験開始に向けて：安全性の検証, 劉雨薇,渡部直史,兼田加珠子,大江一弘,白神宜史,豊嶋厚史,加藤弘樹,巽光朗,下瀬川恵久,畑澤順, 第3回日本核医学会近畿支部会, 2021/07/10
  • Extended single-dose toxicity study of [211At] NaAt in mice for the FIH clinical trial of targeted alpha therapy for differentiated thyroid cancer., SNMMI 2022, 2021/05/01
  • Enhanced therapeutic effect with repeated administration of [211At]NaAt for differentiated thyroid cancer in mice., SNMMI 2022, 2021/05/01
  • Performance evaluation of 18F-FAPI-74 in the FAP expressing pancreatic cancer: preclinical comparison study with 68Ga-FAPI-04., SNMM1 2021 (Jun), 2021/05/01
  • Preparation of dry distilled astatine-211 dissolved in pure water., SNMMI 2022, 2021/05/01
  • Synthetic study of At-211 labeled cancer targeting amino acids, 2021/03/20
  • アスタチン(211At)の酸化還元反応とα線治療薬の創薬研究, 白神 宜史, 第2回日本核医学会分科会放射薬品科学研究会, 2018/09/08
  • Preparation of aqueous solution of 211At-sodium astatide (Na211At) in a high radiochemical purity and its biodistribution study in rats., Shirakami Yoshifumi, WFNMB2018, 2018/04/20
  • Radiolabeling of small molecules with astatine (211At) for theranostics., Shirakami Yoshifumi, BER2018, 2018/03/19
  • A new method for the preparation of astatine-211(211At) and iodine-123(123I) labelled amino acid analogues of phenylalanine, 211At-Phe and 123I-Phe, for radionuclide therapy and SPECT imaging applications, Shirakami Yoshifumi, EANM2018, 2017/10/23

Media Coverage

  • 前立腺がん、体内でα線照射, 2023/01/18
  • 難治性前立腺がんをアルファ線で攻撃 ～阪大発の治療薬を用いた医師主導治験の準備を開始～, 大阪大学, 2022/11
  • がん微小環境まで見える 高感度 FAPI-PET 画像検査 国内初の臨床研究を開始, 大阪大学, 2022/07